RPG Life Sciences Plans Bigger API Push After ₹215 Cr Acquisitions

RPG Life Sciences is expanding its API business after spending ₹215 crore on two acquisitions in five weeks. The company has increased its API manufacturing capacity nearly fivefold to 505 KL, while its customer base has expanded to more than 250. The acquisitions of Actis Generics and Raghava Life Sciences have strengthened the company’s product portfolio, regulatory capabilities and export potential. RPG Life Sciences has ₹500 crore-plus capital available for further acquisitions and expansion. The company is pursuing a buy-and-build strategy focused on differentiated chemistry, merchant APIs, exports and select CDMO opportunities. Watch the exclusive conversation with Ashok Nair, MD, RPG Life Sciences, on Business Today.